Muvalaplin significantly reduces Lp(a) in KRAKEN trial 

The oral inhibitor of Lp(a) particle assembly, muvalaplin, significantly reduced elevated Lp(a) levels in adults at high risk of cardiovascular events in the Phase 2 KRAKEN trial presented at AHA 2024¹ and published simultaneously in JAMA.²